Our xTAG® and MultiCode™-RTx Technologies serve a wide range of clinical applications, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.
Read More
Our xMAP® Technology and its flexible, open-architecture design is used in a wide variety of applications, from academic and clinical research to biodefense and clinical diagnostics.
Read More
Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® technology. Click here to start the conversation now.
Learn More
ARIES® GBS Assay Outperforms Culture Testing in a Multisite Study
Results show excellent clinical performance, sensitivity, specificity, reproducibility, and ease of use
A new publication released in the Journal of Clinical Microbiology reports results of a multisite analysis of the ARIES® GBS Assay. Lead author Diana R. Hernandez from Geisinger, senior author Arundhati Rao from Baylor Scott and White Health, and collaborators issued their findings in the paper entitled “Multicenter Diagnostic Accuracy Evaluation of the Luminex® ARIES® Real-Time PCR Assay for Group B Streptococcus detection in Lim-Enriched samples.”
Continue Reading >
xMAP Technology makes up the basis of Luminex’s core business. This flexible technology is centered on the use of Luminex xMAP Microspheres.
Watch more videos >
June 13
Luminex Initiates Clinical Trials for VERIGENE® II Gastrointestinal Assay
May 18
Luminex Corporation to Present at Upcoming Healthcare Investor Conferences
May 18
Luminex Corporation Declares Second Quarter Cash Dividend
May 7
Luminex Corporation Reports First Quarter 2018 Financial Results
April 16
Luminex Corporation First Quarter Earnings Release Scheduled for May 7, 2018
ECI
2-5 September
Amsterdam, Netherlands
Microbe UK
21-23 September
Sheffield, UK
World Vaccine Congress
29-31 October
Lisbon, Portugal
